On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft guidance issued on 8th May, NICE approved the treatment for people with Duchenne muscular dystrophy (DMD) who are ambulant (able to walk or stand), aged six and older.

Givinostat (brand name Duvyzat) is a histone deacetylase (HDAC) inhibitor that has been shown in clinical trials to slow the progression of Duchenne in ambulant boys. While it is not a cure, evidence suggests that it can help slow down the progression of this relentless disease and preserve muscle function for longer.

It received regulatory approval in the UK in December 2024, following a review by the Medicines and Healthcare products Regulatory Agency (MHRA). The NICE recommendation confirms that givinostat can now be funded for routine use by the NHS in England for those who meet the eligibility criteria.

After a long and challenging NICE appraisal process that lasted almost two years, and 18 months after the treatment was approved as safe and effective by the Medicines and Healthcare products Regulatory Agency (MHRA), this marks a pivotal moment for people with Duchenne.

This development has been driven forward and championed by our friends at Duchenne UK, who played a key role in NICE’s assessment of givinostat and in helping secure this breakthrough – alongside other patient organisations including Muscular Dystrophy UK, Pathfinders Neuromuscular Alliance and Action Duchenne.

There are now two approved treatments for Duchenne available to patients in England and Scotland. This represents significant progress in the treatment of this rare, devastating genetic condition.

As funders of the Duchenne Care UK programme, we are also pleased to highlight that this national care initiative has played a role in disseminating information about this new treatment. The Duchenne Care UK emerging therapies working group, which brings together leading clinicians and patient representatives also developed best practice guidance for clinicians prescribing givinostat.

Click here for further information from Duchenne UK about what this new approval means for families.

Click here to read NICE’s full press release.